Characterization of Chikungunya Virus-Like Particles

被引:21
作者
Noranate, Nitchakarn [1 ]
Takeda, Naokazu [1 ,3 ]
Chetanachan, Prukswan [2 ]
Sittisaman, Pathompong [2 ]
A-nuegoonpipat, Atchareeya [2 ]
Anantapreecha, Surapee [2 ]
机构
[1] Thailand Japan Res Collaborat Ctr Emerging & Reem, Nonthaburi, Thailand
[2] Minist Publ Hlth, Dept Med Sci, Natl Inst Hlth, Nonthaburi, Thailand
[3] Osaka Univ, Microbial Dis Res Inst, Osaka, Japan
关键词
SEMLIKI-FOREST-VIRUS; CHOLESTEROL DEPENDENCE; VACCINE; PROTEIN; INFECTION; FUSION; CELLS; E2; ALPHAVIRUSES; MICE;
D O I
10.1371/journal.pone.0108169
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Chikungunya virus (CHIKV) is becoming a global concern due to the increasing number of outbreaks throughout the world and the absence of any CHIKV-specific vaccine or treatment. Virus-like particles (VLPs) are multistructured proteins that mimic the organization and conformation of native viruses but lack the viral genome. They are noninfectious and potentially safer vaccine candidates. Recent studies demonstrated that the yield of CHIKV VLPs varies depending on the strains, despite the 95% amino acid similarity of the strains. This might be due to the codon usage, since protein expression is differently controlled by different organisms. We optimized the region encoding CHIKV structural proteins, C-E3-E2-6k-E1, inserted it into a mammalian expression vector, and used the resulting construct to transfect 293 cells. We detected 50-kDa proteins corresponding to E1 and/or E2 in the cell lysate and the supernatant. Transmission electron microscopy revealed spherical particles with a 50-to 60-nm diameter in the supernatant that resembled the native CHIKV virions. The buoyant density of the VLPs was 1.23 g/mL, and the yield was 20 mg purified VLPs per 10 8 cells. The VLPs aggregated when mixed with convalescent sera from chikungunya patients, indicating that their antigenicity is similar to that of native CHIKV. Antibodies elicited with the VLPs were capable of detecting native CHIKV, demonstrating that the VLPs retain immunogenicity similar to that of the native virion. These results indicated that CHIKV VLPs are morphologically, antigenically, and immunologically similar to the native CHIKV, suggesting that they have potential for use in chikungunya vaccines.
引用
收藏
页数:8
相关论文
共 46 条
[1]   A Specific Domain of the Chikungunya Virus E2 Protein Regulates Particle Formation in Human Cells: Implications for Alphavirus Vaccine Design [J].
Akahata, Wataru ;
Nabel, Gary J. .
JOURNAL OF VIROLOGY, 2012, 86 (16) :8879-8883
[2]   A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection [J].
Akahata, Wataru ;
Yang, Zhi-Yong ;
Andersen, Hanne ;
Sun, Siyang ;
Holdaway, Heather A. ;
Kong, Wing-Pui ;
Lewis, Mark G. ;
Higgs, Stephen ;
Rossmann, Michael G. ;
Rao, Srinivas ;
Nabel, Gary J. .
NATURE MEDICINE, 2010, 16 (03) :334-U134
[3]   CHROMATOGRAPHIC-SEPARATION OF POLYOMA-VIRUS PROTEINS AND RENATURATION OF ISOLATED VP1 MAJOR CAPSID PROTEIN [J].
BRADY, JN ;
CONSIGLI, RA .
JOURNAL OF VIROLOGY, 1978, 27 (02) :436-442
[4]   A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus [J].
Brandler, Samantha ;
Ruffle, Claude ;
Combredet, Chantal ;
Brault, Jean-Baptiste ;
Najburg, Valerie ;
Prevost, Marie-Christine ;
Habel, Andre ;
Tauber, Erich ;
Despres, Philippe ;
Tangy, Frederic .
VACCINE, 2013, 31 (36) :3718-3725
[5]  
Buonaguro L, 2011, EXPERT REV VACCINES, V10, P1569, DOI [10.1586/ERV.11.135, 10.1586/erv.11.135]
[6]   Chikungunya: a re-emerging virus [J].
Burt, Felicity J. ;
Rolph, Micheal S. ;
Rulli, Nestor E. ;
Mahalingam, Suresh ;
Heise, Mark T. .
LANCET, 2012, 379 (9816) :662-671
[7]   Prophylaxis and Therapy for Chikungunya Virus Infection [J].
Couderc, Therese ;
Khandoudi, Nassirah ;
Grandadam, Marc ;
Visse, Catherine ;
Gangneux, Nicolas ;
Bagot, Sebastien ;
Prost, Jean-Francois ;
Lecuit, Marc .
JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (04) :516-523
[8]   Recombinant HIV-1 Pr55gag virus-like particles:: potent stimulators of innate and acquired immune responses [J].
Deml, L ;
Speth, C ;
Dierich, MP ;
Wolf, H ;
Wagner, R .
MOLECULAR IMMUNOLOGY, 2005, 42 (02) :259-277
[9]   CHIKUNGUNYA VIRUS VACCINE PREPARED BY TWEEN-ETHER EXTRACTION [J].
ECKELS, KH ;
HARRISON, VR ;
HETRICK, FM .
APPLIED MICROBIOLOGY, 1970, 19 (02) :321-&
[10]   Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218 [J].
Edelman, R ;
Tacket, CO ;
Wasserman, SS ;
Bodison, SA ;
Perry, JG ;
Mangiafico, JA .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2000, 62 (06) :681-685